Favorable clinical and safety outcomes independent of baseline skin disease burden in treatment-naïve blastic plasmacytoid dendritic cell neoplasm treated with tagraxofusp: a subgroup analysis of a pivotal trial
Acta Haematologica · 2026-10-29
DOI: 10.1159/aha/abkag017 ↗Abstract
Introduction: Although blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a hematologic malignancy, approximately 90% of patients present with skin disease. To determine whether baseline skin disease burden in BPDCN impacts efficacy and safety of first-line tagraxofusp, a subgroup analysis of a multicenter phase 1/2 trial (NCT02113982) was conducted with a modified Severity-Weighted Assessment Tool (mSWAT), an objective quantification of skin involvement utilized for response assessment. Methods: Patients who received first-line tagraxofusp were stratified by high (n=31) or low (n=31) baseline mSWAT scores. Results: Both groups had baseline BPDCN skin involvement (100% in mSWAT high and 90% in mSWAT low). Complete response/clinical complete response rate was 58% in both groups. Median overall survival (OS) was 25.8 (high) versus 12.0 months (low). After excluding those with prior/concomitant hematologic malignancies, median OS was 27.7 (high) versus 18.2 months (low). Among patients bridged to hematopoietic stem cell transplantation, median OS was not reached (high) versus 38.4 months (low). Adverse event profiles were similar. Conclusion: Tagraxofusp demonstrated clinically meaningful benefit independent of baseline skin disease burden, supporting its use as first-line, standard-of-care therapy in BPDCN.
EUVIMED